JP2024516825A - トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン - Google Patents

トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン Download PDF

Info

Publication number
JP2024516825A
JP2024516825A JP2023566472A JP2023566472A JP2024516825A JP 2024516825 A JP2024516825 A JP 2024516825A JP 2023566472 A JP2023566472 A JP 2023566472A JP 2023566472 A JP2023566472 A JP 2023566472A JP 2024516825 A JP2024516825 A JP 2024516825A
Authority
JP
Japan
Prior art keywords
compound
administered
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516825A5 (enExample
Inventor
パラルカル，ビシュワス
ピー デシリス，アーサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybrexa 2 Inc
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of JP2024516825A publication Critical patent/JP2024516825A/ja
Publication of JP2024516825A5 publication Critical patent/JP2024516825A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023566472A 2021-04-29 2022-04-28 トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン Pending JP2024516825A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
US63/181,640 2021-04-29
PCT/US2022/071967 WO2022232808A1 (en) 2021-04-29 2022-04-28 Dosing regimens of peptide conjugates of topoisomerase i inhibitors

Publications (2)

Publication Number Publication Date
JP2024516825A true JP2024516825A (ja) 2024-04-17
JP2024516825A5 JP2024516825A5 (enExample) 2025-05-09

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566472A Pending JP2024516825A (ja) 2021-04-29 2022-04-28 トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン

Country Status (12)

Country Link
US (1) US20240226308A1 (enExample)
EP (1) EP4329817A1 (enExample)
JP (1) JP2024516825A (enExample)
KR (1) KR20240019097A (enExample)
CN (1) CN117897175A (enExample)
AU (1) AU2022267389A1 (enExample)
CA (1) CA3218253A1 (enExample)
CL (1) CL2023003187A1 (enExample)
IL (1) IL308052A (enExample)
MX (1) MX2023012779A (enExample)
TW (1) TW202308696A (enExample)
WO (1) WO2022232808A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
EP4321168A3 (en) 2010-07-13 2024-04-24 Yale University, Inc. Environmentally sensitive compositions
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
MX2022000449A (es) * 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.

Also Published As

Publication number Publication date
AU2022267389A1 (en) 2023-11-09
US20240226308A1 (en) 2024-07-11
CL2023003187A1 (es) 2024-05-03
MX2023012779A (es) 2024-01-16
IL308052A (en) 2023-12-01
CN117897175A (zh) 2024-04-16
WO2022232808A1 (en) 2022-11-03
EP4329817A1 (en) 2024-03-06
KR20240019097A (ko) 2024-02-14
TW202308696A (zh) 2023-03-01
CA3218253A1 (en) 2022-11-03
AU2022267389A9 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP2024516825A (ja) トポイソメラーゼｉ阻害剤のペプチドコンジュゲートの投与レジメン
JP2024545125A (ja) Ｓｔａｔ３分解剤およびその使用
EP3735267B1 (en) Adminsitration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
EP2054061A2 (en) Combination therapy
CA3018145C (en) TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
JP6878431B2 (ja) がんに対するメルフルフェン投薬計画
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
KR20220003560A (ko) 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염
US20190212341A1 (en) Methods for treating colorectal and metastatic colorectal cancers
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
US20230116137A1 (en) Methods for treating colorectal and metastatic colorectal cancers
CN118414173A (zh) 抗体-药物缀合物和parp1选择性抑制剂的组合
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
CN115190800A (zh) 一种brd4抑制剂的用途
WO2025166944A1 (en) Methods of treatment using an ezh2 modulator
WO2024258916A1 (en) Stat3 degraders and uses thereof
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
Tolcher et al. 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial
EP3976036A1 (en) Methods and uses for treating cancer
HK40040066B (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
TW201121547A (en) Pharmaceutical composition for the treatment of proliferative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425